For example, elevated Asporin (ASPN) expression in oxaliplatin-resistant CRC was targeted using nanoparticles co-delivering ASPN-siRNA and oxaliplatin, resulting in improved anti-tumor activity in vitro and in vivo (170). The gene discussed is ASPN; the disease is colorectal carcinoma.